Web31 oct. 2024 · 簡介 目錄. 在CD47抑製劑的開發中,一期產品約有17種,佔總數的49%。. CD47 管道由位於前十名的美國生物技術公司主導。. 這些公司佔臨床階段 CD47 總管線的約 45%。. 本報告調查分化抗原組 47 (CD47) 抑製劑,詳細分析主要管道產品的開發階段、公司 … WebContent - SummaryCellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) pipeline Target constitutes close
分化抗原組 47 (CD47) 抑製劑:管道分析 (2024) - 日商環球訊息有 …
WebBrowse U.S. Federal Trademarks (USPTO) that list Lynkcell, Inc. as Trademark Correspondent : Trademark Elite. TrademarkElite.com provides online trademark search … Web16 apr. 2024 · Lynkcell is developing and commercializing small molecules and antibodies for cancer and other serious diseases. Their lead candidate, LYN00101 (monoclonal antibody), which blocks the Vascular endothelial growth factor (VEGF) pathway. It is being indicated for various types of cancer. The candidate has completed phase III clinical trials. hill country luxury living hunt texas
Lynkcell - Overview, News & Competitors ZoomInfo.com
WebFind company research, competitor information, contact details & financial data for Liquicell Technologies Inc of Minneapolis, MN. Get the latest business insights from Dun & … WebCompany profile page for LynkTel Inc including stock price, company news, press releases, executives, board members, and contact information WebCellular Tumor Antigen p53 - Pipeline Review, H2 2024 Cellular Tumor Antigen p53 - Pipeline Review, H2 2024 Summary Cellular Tumor Antigen p53 (Tumor Suppressor p53 … hill country market days schedule